Pricing Log in Create free account
Friday 6 November 2026 Export HCM’s income statement to Excel — free account

HUTCHMED (China) Limited Sponsored ADR

HCM Healthcare Drug Manufacturers Specialty & Generic

HUTCHMED (China) Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $548.5 million, down 13.0% from fiscal 2024.

14.27 0.35 +2.51%
Market cap
$2.5B
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
4/9
Altman Z
3.53
Beneish M
−1.20
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

HUTCHMED (China) Limited Sponsored ADR (HCM) EV/EBITDA

Alert me on EV/EBITDA

As of 5 November 2026, HUTCHMED (China) Limited Sponsored ADR (HCM) trades at a EV/EBITDA of 0.4×. Over the past ten years it has ranged from 0.0× (December 2018) to 2.1× (June 2021); the current reading is higher than 98% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 12.2× and below the Healthcare sector median of 8.4×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 0.4× 69.15%
FY2024 0.2× (6.66%)
FY2023 0.2× 103.62%
FY2022 0.1× (65.60%)
FY2021 0.3× 62.09%
FY2020 0.2× 99.16%
FY2019 0.1× (62.01%)
FY2018 0.3× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period EV/EBITDA Change
Jun 2023 0.0× —
Dec 2022 0.0× —
Jun 2022 0.0× —
Jun 2021 0.0× —
10 more quarters

Against its own ten years

Low 0.0× High 2.1×
Ten-year median 0.2×
Current reading's percentile 98

EV/EBITDA against peers

Company EV/EBITDA
PRGO Perrigo Company plc compare n/m
BCRX BioCryst Pharmaceuticals, Inc. compare n/m
ALVO Alvotech compare n/m
TRLV Trulieve Cannabis Corp. compare n/m
HCM HUTCHMED (China) Limited Sponsored ADR 0.4×
RGC Regencell Bioscience Holdings Limited compare 1.1×
ANIP ANI Pharmaceuticals, Inc. compare 6.9×
PBH Prestige Consumer Healthcare Inc. compare 12.4×
XERS Xeris Biopharma Holdings, Inc. compare 46.6×
Drug Manufacturers Specialty & Generic industry median 12.2×
Healthcare sector median 8.4×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on HCM